🚀 VC round data is live in beta, check it out!
Arcturus Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Arcturus Therapeutics and similar public comparables like Procaps Group, Camp4 Therapeutics, Eledon Pharmaceuticals, Binex and more.
Arcturus Therapeutics Overview
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
Founded
2008
HQ
Employees
176
Website
Sectors
Financials (LTM)
EV
$28M
Arcturus Therapeutics Financials
Arcturus Therapeutics reported last 12-month revenue of $70M and negative EBITDA of ($88M).
In the same LTM period, Arcturus Therapeutics generated $68M in gross profit, ($88M) in EBITDA losses, and had net loss of ($79M).
Revenue (LTM)
Arcturus Therapeutics P&L
In the most recent fiscal year, Arcturus Therapeutics reported revenue of $82M and EBITDA of ($63M).
Arcturus Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $70M | XXX | $82M | XXX | XXX | XXX |
| Gross Profit | $68M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 98% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($88M) | XXX | ($63M) | XXX | XXX | XXX |
| EBITDA Margin | (126%) | XXX | (76%) | XXX | XXX | XXX |
| EBIT Margin | (127%) | XXX | (93%) | XXX | XXX | XXX |
| Net Profit | ($79M) | XXX | ($66M) | XXX | XXX | XXX |
| Net Margin | (114%) | XXX | (80%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Arcturus Therapeutics Stock Performance
Arcturus Therapeutics has current market cap of $234M, and enterprise value of $28M.
Market Cap Evolution
Arcturus Therapeutics' stock price is $8.24.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $28M | $234M | -3.0% | XXX | XXX | XXX | $-2.31 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialArcturus Therapeutics Valuation Multiples
Arcturus Therapeutics trades at 0.4x EV/Revenue multiple, and (0.3x) EV/EBITDA.
EV / Revenue (LTM)
Arcturus Therapeutics Financial Valuation Multiples
As of April 10, 2026, Arcturus Therapeutics has market cap of $234M and EV of $28M.
Equity research analysts estimate Arcturus Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Arcturus Therapeutics has a P/E ratio of (3.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $234M | XXX | $234M | XXX | XXX | XXX |
| EV (current) | $28M | XXX | $28M | XXX | XXX | XXX |
| EV/Revenue | 0.4x | XXX | 0.3x | XXX | XXX | XXX |
| EV/EBITDA | (0.3x) | XXX | (0.4x) | XXX | XXX | XXX |
| EV/EBIT | (0.3x) | XXX | (0.4x) | XXX | XXX | XXX |
| EV/Gross Profit | 0.4x | XXX | — | XXX | XXX | XXX |
| P/E | (3.0x) | XXX | (3.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Arcturus Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Arcturus Therapeutics Margins & Growth Rates
Arcturus Therapeutics' revenue in the last 12 month declined by (45%).
Arcturus Therapeutics' revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.8M for the same period.
Arcturus Therapeutics' rule of 40 is (387%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Arcturus Therapeutics' rule of X is (454%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Arcturus Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (45%) | XXX | (55%) | XXX | XXX | XXX |
| EBITDA Margin | (126%) | XXX | (76%) | XXX | XXX | XXX |
| EBITDA Growth | 46% | XXX | 102% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (387%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (454%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 68% | XXX | 56% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 158% | XXX | 137% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 175% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Arcturus Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Procaps Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Camp4 Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Eledon Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Binex | XXX | XXX | XXX | XXX | XXX | XXX |
| Voyager Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Arcturus Therapeutics M&A Activity
Arcturus Therapeutics acquired XXX companies to date.
Last acquisition by Arcturus Therapeutics was on XXXXXXXX, XXXXX. Arcturus Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Arcturus Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialArcturus Therapeutics Investment Activity
Arcturus Therapeutics invested in XXX companies to date.
Arcturus Therapeutics made its latest investment on XXXXXXXX, XXXXX. Arcturus Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Arcturus Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Arcturus Therapeutics
| When was Arcturus Therapeutics founded? | Arcturus Therapeutics was founded in 2008. |
| Where is Arcturus Therapeutics headquartered? | Arcturus Therapeutics is headquartered in United States. |
| How many employees does Arcturus Therapeutics have? | As of today, Arcturus Therapeutics has over 176 employees. |
| Who is the CEO of Arcturus Therapeutics? | Arcturus Therapeutics' CEO is Joseph E. Payne. |
| Is Arcturus Therapeutics publicly listed? | Yes, Arcturus Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Arcturus Therapeutics? | Arcturus Therapeutics trades under ARCT ticker. |
| When did Arcturus Therapeutics go public? | Arcturus Therapeutics went public in 2013. |
| Who are competitors of Arcturus Therapeutics? | Arcturus Therapeutics main competitors are Procaps Group, Camp4 Therapeutics, Eledon Pharmaceuticals, Binex. |
| What is the current market cap of Arcturus Therapeutics? | Arcturus Therapeutics' current market cap is $234M. |
| What is the current revenue of Arcturus Therapeutics? | Arcturus Therapeutics' last 12 months revenue is $70M. |
| What is the current revenue growth of Arcturus Therapeutics? | Arcturus Therapeutics revenue growth (NTM/LTM) is (45%). |
| What is the current EV/Revenue multiple of Arcturus Therapeutics? | Current revenue multiple of Arcturus Therapeutics is 0.4x. |
| Is Arcturus Therapeutics profitable? | No, Arcturus Therapeutics is not profitable. |
| What is the current EBITDA of Arcturus Therapeutics? | Arcturus Therapeutics has negative EBITDA and is not profitable. |
| What is Arcturus Therapeutics' EBITDA margin? | Arcturus Therapeutics' last 12 months EBITDA margin is (126%). |
| What is the current EV/EBITDA multiple of Arcturus Therapeutics? | Current EBITDA multiple of Arcturus Therapeutics is (0.3x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.